Drug Trial Radar · NCT02498782
Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease
Last checked: Nov 20, 2026Latest source record: Jul 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Jul 2014
Primary completion
Sep 2015
Study completion Feb 2016
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The hypothesis is to evaluate if the treatment with Fexinidazole will lead to a better sustained clearance of the parasites at 6 months of follow-up when in comparison to placebo in patients with chronic indeterminate CD.
Conditions
- Chagas Disease
- Trypanosomiasis, South American
- South American Trypanosomiasis
- Disease, Chagas
Interventions
FexinidazoleDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parasitological cure rate (PCR)Time frame: 8 weeks and sustained until 6 months
- Adverse eventsTime frame: 7 months
- Serious Adverse eventsTime frame: 7 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Plataforma Atención Integral de Pacientes con Enfermedad de Chagas
Cochabamba, Bolivia · Recruiting
Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas
Tarija, Bolivia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.